1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef]
2. Quan, J.; Johnson, N.; Zhou, G.-B.; Parsons, P.; Boyle, G.; Gao, J. Potential molecular targets for inhibiting bone invasion by oral squamous cell carcinoma: A review of mechanisms. Cancer Metastasis Rev. 2011, 31, 209–219. [CrossRef]
3. Petersen, P.E. Oral cancer prevention and control—The approach of the World Health Organization. Oral Oncol 2009, 45, 454–460. [CrossRef]
4. Anzai, H.; Yoshimoto, S.; Okamura, K.; Hiraki, A.; Hashimoto, S. IDO1-mediated Trp-kynurenine-AhR signal activation induces stemness and tumor dormancy in oral squamous cell carcinomas. Oral Sci. Int. 2021. [CrossRef]
5. Meng, X.; Mori, T.; Matsumoto, F.; Miura, N.; Onidani, K.; Kobayashi, K.; Matsuzaki, Y.; Yoshimoto, S.; Ikeda, K.; Honda, K. Hepatitis B X-interacting protein, involved in increasing proliferation and cell migration, is a prognostic marker in head and neck squamous cell carcinoma. Oral Sci. Int. 2021. [CrossRef]
6. Pollard, J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4, 71–78. [CrossRef]
7. Mantovani, A.; Sozzani, S.; Locati, M.; Allavena, P.; Sica, A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23, 549–555. [CrossRef]
8. Mills, C.D. M1 and M2 Macrophages: Oracles of Health and Disease. Crit. Rev. Immunol. 2012, 32, 463–488. [CrossRef]
9. Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3, 23–35. [CrossRef]
10. Wynn, T.A.; Chawla, A.; Pollard, J.W. Macrophage biology in development, homeostasis and disease. Nature 2013, 496, 445–455. [CrossRef]
11. Fujimura, T.; Kambayashi, Y.; Fujisawa, Y.; Hidaka, T.; Aiba, S. Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer. Front. Oncol. 2018, 8, 3. [CrossRef] [PubMed]
12. Zwadlo-Klarwasser, G.; Neubert, R.; Stahlmann, R.; Schmutzler, W. Influence of dexamethasone on the RM 3/1-positive macrophages in the peripheral blood and tissues of a New World monkey (the marmoset Callithrix jacchus). Int. Arch. Allergy Immunol. 1992, 97, 178–180. [CrossRef] [PubMed]
13. Fabriek, B.O.; Dijkstra, C.D.; van den Berg, T.K. The macrophage scavenger receptor CD163. Immunobiology 2005, 210, 153–160. [CrossRef]
14. Komohara, Y.; Niino, D.; Saito, Y.; Ohnishi, K.; Horlad, H.; Ohshima, K.; Takeya, M. Clinical significance of CD 163 + tumor- associated macrophages in patients with adult T-cell leukemia/lymphoma. Cancer Sci. 2013, 104, 945–951. [CrossRef] [PubMed]
15. Berwin, B.; Hart, J.P.; Rice, S.; Gass, C.; Pizzo, S.V.; Post, S.; Nicchitta, C.V. Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells. EMBO J. 2003, 22, 6127–6136. [CrossRef]
16. Krieger, M. The other side of scavenger receptors: Pattern recognition for host defense. Curr. Opin. Lipidol. 1997, 8, 275–280. [CrossRef]
17. Ohnishi, K.; Komohara, Y.; Fujiwara, Y.; Takemura, K.; Lei, X.; Nakagawa, T.; Sakashita, N.; Takeya, M. Suppression of TLR4- mediated inflammatory response by macrophage class A scavenger receptor (CD204). Biochem. Biophys. Res. Commun. 2011, 411, 516–522. [CrossRef] [PubMed]
18. Platt, N.; Gordon, S. Is the class A macrophage scavenger receptor (SR-A) multifunctional?—The mouse’s tale. J. Clin. Investig. 2001, 108, 649–654. [CrossRef] [PubMed]
19. Kubota, K.; Moriyama, M.; Furukawa, S.; Rafiul, H.; Maruse, Y.; Jinno, T.; Tanaka, A.; Ohta, M.; Ishiguro, N.; Yamauchi, M.; et al. CD163(+)CD204(+) tumor-associated macrophages contribute to T cell regulation via interleukin-10 and PD-L1 production in oral squamous cell carcinoma. Sci. Rep. 2017, 7, 1755. [CrossRef]
20. Azad, A.K.; Rajaram, M.V.S.; Schlesinger, L.S. Exploitation of the Macrophage Mannose Receptor (CD206) in Infectious Disease Diagnostics and Therapeutics. J. Cytol. Mol. Biol. 2014, 1, 1000003. [CrossRef]
21. Hu, W.; Qian, Y.; Yu, F.; Liu, W.; Wu, Y.; Fang, X.; Hao, W. Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma. Oncol. Lett. 2015, 10, 1390–1396. [CrossRef] [PubMed]
22. Dong, P.; Ma, L.; Liu, L.; Zhao, G.; Zhang, S.; Dong, L.; Xue, R.; Chen, S. CD86+/CD206+, Diametrically Polarized Tumor- Associated Macrophages, Predict Hepatocellular Carcinoma Patient Prognosis. Int. J. Mol. Sci. 2016, 17, 320. [CrossRef] [PubMed]
23. Haque, A.; Moriyama, M.; Kubota, K.; Ishiguro, N.; Sakamoto, M.; Chinju, A.; Mochizuki, K.; Sakamoto, T.; Kaneko, N.; Munemura, R.; et al. CD206(+) tumor-associated macrophages promote proliferation and invasion in oral squamous cell carcinoma via EGF production. Sci. Rep. 2019, 9, 14611. [CrossRef] [PubMed]
24. Kelly, F.L.; Weinberg, K.E.; Nagler, A.E.; Nixon, A.B.; Star, M.D.; Todd, J.L.; Brass, D.M.; Palmer, S.M. EGFR-Dependent IL8 Production by Airway Epithelial Cells After Exposure to the Food Flavoring Chemical 2,3-Butanedione. Toxicol. Sci. 2019, 169, 534–542. [CrossRef]
25. Freytag, J.; Wilkins-Port, C.E.; Higgins, C.E.; Higgins, S.P.; Samarakoon, R.; Higgins, P.J. PAI-1 mediates the TGF-beta1+EGF- induced “scatter” response in transformed human keratinocytes. J. Investig. Dermatol. 2010, 130, 2179–2190. [CrossRef]
26. Qian, B.-Z.; Pollard, J.W. Macrophage Diversity Enhances Tumor Progression and Metastasis. Cell 2010, 141, 39–51. [CrossRef]
27. Komohara, Y.; Jinushi, M.; Takeya, M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 2013, 105, 1–8. [CrossRef]
28. Li, X.; Bu, W.; Meng, L.; Liu, X.; Wang, S.; Jiang, L.; Ren, M.; Fan, Y.; Sun, H. CXCL12/CXCR4 pathway orchestrates CSC-like properties by CAF recruited tumor associated macrophage in OSCC. Exp. Cell Res. 2019, 378, 131–138. [CrossRef]
29. Teixeira, L.R.; Almeida, L.Y.; Silva, R.N.; Mesquita, A.T.M.; Colturato, C.B.N.; Silveira, H.A.; Duarte, A.; Ribeiro-Silva, A.; Leon, J.E. Young and elderly oral squamous cell carcinoma patients present similar angiogenic profile and predominance of M2 macrophages: Comparative immunohistochemical study. Head Neck 2019, 41, 4111–4120. [CrossRef] [PubMed]
30. Li, J.-J.; Mao, X.-H.; Tian, T.; Wang, W.-M.; Su, T.; Jiang, C.-H.; Hu, C.-Y. Role of PFKFB3 and CD163 in Oral Squamous Cell Carcinoma Angiogenesis. Curr. Med. Sci. 2019, 39, 410–414. [CrossRef]
31. Kouketsu, A.; Sato, I.; Oikawa, M.; Shimizu, Y.; Saito, H.; Tashiro, K.; Yamashita, Y.; Takahashi, T.; Kumamoto, H. Regulatory T cells and M2-polarized tumour-associated macrophages are associated with the oncogenesis and progression of oral squamous cell carcinoma. Int. J. Oral Maxillofac. Surg. 2019, 48, 1279–1288. [CrossRef]
32. Stasikowska-Kanicka, O.; Wa˛growska-Danilewicz, M.; Danilewicz, M. CD8+ and CD163+ infiltrating cells and PD-L1 immunoex- pression in oral leukoplakia and oral carcinoma. APMIS 2018, 126, 732–738. [CrossRef]
33. Sun, H.; Miao, C.; Liu, W.; Qiao, X.; Yang, W.; Li, L.; Li, C. TGF-beta1/TbetaRII/Smad3 signaling pathway promotes VEGF expression in oral squamous cell carcinoma tumor-associated macrophages. Biochem. Biophys. Res. Commun. 2018, 497, 583–590. [CrossRef]
34. Yamagata, Y.; Tomioka, H.; Sakamoto, K.; Sato, K.; Harada, H.; Ikeda, T.; Kayamori, K. CD163-Positive Macrophages Within the Tumor Stroma Are Associated with Lymphangiogenesis and Lymph Node Metastasis in Oral Squamous Cell Carcinoma. J. Oral Maxillofac. Surg. 2017, 75, 2144–2153. [CrossRef] [PubMed]
35. Takahashi, H.; Sakakura, K.; Kudo, T.; Toyoda, M.; Kaira, K.; Oyama, T.; Chikamatsu, K. Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages. Oncotarget 2016, 8, 8633–8647. [CrossRef] [PubMed]
36. Jiang, C.; Yuan, F.; Wang, J.; Wu, L. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages. Immunobiology 2017, 222, 651–657. [CrossRef] [PubMed]
37. Okubo, M.; Kioi, M.; Nakashima, H.; Sugiura, K.; Mitsudo, K.; Aoki, I.; Taniguchi, H.; Tohnai, I. M2-polarized macro-phages contribute to neovasculogenesis, leading to relapse of oral cancer following radiation. Sci. Rep. 2016, 6, 27548. [CrossRef] [PubMed]
38. Hu, Y.; He, M.Y.; Zhu, L.F.; Yang, C.C.; Zhou, M.L.; Wang, Q.; Zhang, W.; Zheng, Y.Y.; Wang, D.M.; Xu, Z.Q.; et al. Tumor- associated macrophages correlate with the clinicopathological features and poor outcomes via inducing epithelial to mesenchymal transition in oral squamous cell carcinoma. J. Exp. Clin. Cancer Res. 2016, 35, 12. [CrossRef]
39. Nishio, K.; Motozawa, K.; Omagari, D.; Gojoubori, T.; Ikeda, T.; Asano, M.; Gionhaku, N. Comparison of MMP2 and MMP9 expression levels between primary and metastatic regions of oral squamous cell carcinoma. J. Oral Sci. 2016, 58, 59–65. [CrossRef]
40. Chiu, K.-C.; Lee, C.-H.; Liu, S.-Y.; Chou, Y.-T.; Huang, R.-Y.; Huang, S.-M.; Shieh, Y.-S. Polarization of tumor-associated macrophages and Gas6/Axl signaling in oral squamous cell carcinoma. Oral Oncol. 2015, 51, 683–689. [CrossRef]
41. Wang, S.; Sun, M.; Gu, C.; Wang, X.; Chen, D.; Zhao, E.; Jiao, X.; Zheng, J. Expression of CD163, interleukin-10, and interferon-gamma in oral squamous cell carcinoma: Mutual relationships and prognostic implications. Eur. J. Oral Sci. 2014, 122, 202–209. [CrossRef]
42. Matsuoka, Y.; Yoshida, R.; Nakayama, H.; Nagata, M.; Hirosue, A.; Tanaka, T.; Kawahara, K.; Nakagawa, Y.; Sakata, J.; Arita, H.; et al. The tumour stromal features are associated with resistance to 5-FU-based chemoradiotherapy and a poor prognosis in patients with oral squamous cell carcinoma. APMIS 2015, 123, 205–214. [CrossRef]
43. Fujita, Y.; Okamoto, M.; Goda, H.; Tano, T.; Nakashiro, K.-I.; Sugita, A.; Fujita, T.; Koido, S.; Homma, S.; Kawakami, Y.; et al. Prognostic Significance of Interleukin-8 and CD163-Positive Cell-Infiltration in Tumor Tissues in Patients with Oral Squamous Cell Carcinoma. PLoS ONE 2014, 9, e110378. [CrossRef]
44. Lee, C.H.; Liu, S.Y.; Chou, K.C.; Yeh, C.T.; Shiah, S.G.; Huang, R.Y.; Cheng, J.C.; Yen, C.Y.; Shieh, Y.S. Tumor-associated macrophages promote oral cancer progression through activation of the Axl signaling pathway. Ann. Surg. Oncol. 2014, 21, 1031–1037. [CrossRef]
45. He, K.-F.; Zhang, L.; Huang, C.-F.; Ma, S.-R.; Wang, Y.-F.; Wang, W.-M.; Zhao, Z.; Liu, B.; Zhao, Y.-F.; Zhang, W.-F.; et al. CD163+ Tumor-Associated Macrophages Correlated with Poor Prognosis and Cancer Stem Cells in Oral Squamous Cell Carcinoma. BioMed Res. Int. 2014, 2014, 1–9. [CrossRef] [PubMed]
46. Boas, D.S.; Takiya, C.M.; Gurgel, C.A.; Cabral, M.G.; Santos, J.N. Tumor-infiltrating macrophage and microvessel density in oral squamous cell carcinoma. Braz. Dent. J. 2013, 24, 194–199. [CrossRef]
47. Fujii, N.; Shomori, K.; Shiomi, T.; Nakabayashi, M.; Takeda, C.; Ryoke, K.; Ito, H. Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: Their clinicopathological and prognostic significance. J. Oral Pathol. Med. 2012, 41, 444–451. [CrossRef] [PubMed]
48. Mori, K.; Hiroi, M.; Shimada, J.; Ohmori, Y. Infiltration of m2 tumor-associated macrophages in oral squamous cell carcinoma correlates with tumor malignancy. Cancers 2011, 3, 3726–3739. [CrossRef] [PubMed]
49. El-Rouby, D.H. Association of macrophages with angiogenesis in oral verrucous and squamous cell carcinomas. J. Oral Pathol. Med. 2010, 39, 559–564. [CrossRef]
50. Agarbati, S.; Mascitti, M.; Paolucci, E.; Togni, L.; Santarelli, A.; Rubini, C.; Fazioli, F. Prognostic Relevance of Macrophage Phenotypes in High-grade Oral Tongue Squamous Cell Carcinomas. Appl. Immunohistochem. Mol. Morphol. 2021, 29, 359–365. [CrossRef]
論文の公開元へ
